Daisy Wolf
Showing 1–2 of 2 transcripts.
- a16z51 min
Andrew Huberman: Peptides, Sleep Tech, and the End of Obesity
Professor Andrew Huberman outlined a major shift in consumer health toward proactive management driven by the pandemic, highlighting the transformative impact of GLP-1 drugs and non-GLP peptides on obesity treatment and tissue repair. The discussion detailed critical nutritional and circadian interventions, such as strategic carbohydrate timing and core-body cooling, alongside emerging AI diagnostics and "write-to-biology" technologies aimed at extending human lifespan toward one hundred years. Huberman further emphasized the need for scientific literacy amidst political polarization while predicting rapid adoption of sleep optimization devices and real-time biomarker monitoring within the next five years.
- a16z46 min
Hey Tech, Come to Healthcare
In a 2022 analysis, analysts BJ and Daisy predict that consumer health technology will produce the world's first trillion-dollar company by leveraging a $4 trillion U.S. market where 88% of the population faces metabolic challenges. The event details how artificial intelligence and post-pandemic cultural shifts are enabling a transition from reactive sick care to predictive, home-centric prevention while bypassing traditional incumbent barriers through new "payvider," marketplace, and financial infrastructure models. These strategies aim to unify fragmented health data and engineer behavioral change, ultimately positioning tech founders with hybrid clinical expertise to replace legacy systems with AI-driven, high-UX solutions.